igm-803-1200-02

Overview

We are a biotechnology company pioneering the development of engineered IgM antibodies. IgM antibodies have inherent properties that we believe may enable them to improve upon the efficacy and safety of IgG antibodies in multiple therapeutic applications.

We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Our lead product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3, that is currently in a Phase 1 clinical trial for the treatment of relapsed/refractory B cell Non-Hodgkin’s lymphoma (NHL).  Our second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5), that is currently in a Phase 1 clinical trial for the treatment of solid cancers and NHL.  Also in our product pipeline is IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

IgM antibodies have 10 binding units compared to 2 for IgG antibodies. This inherent biological advantage enables:

  • Stronger binding to cell surface targets, including those with low expression levels, which may result in better and more complete targeting of cancer cells;
  • Stronger binding to difficult targets, such as tumor associated carbohydrates and glycosylated proteins, which has the potential to expand the range of addressable cancer targets;
  • Greater ability to cross-link cell surface receptors, which may significantly enhance cellular signaling for killing cancer cells or stimulating T cells; and
  • Substantially greater ability to utilize the complement dependent cytotoxicity (CDC) mechanism of killing targeted cells, which kills cancer cells without requiring the presence of immune cells.

We believe that we have the most advanced research and development program focused on engineered therapeutic IgM antibodies. We have created a portfolio of patents and patent applications, know-how and trade secrets directed to our platform technology, product candidates and manufacturing capabilities, and we retain worldwide commercial rights to all of our product candidates and intellectual property.

IGM is a well-funded company that is growing rapidly.  We are looking to add motivated individuals who will be as passionate about our mission as we are at our headquarters in Mountain View, California.  Join Us.

Contact Us

IGM Biosciences, Inc.
325 East Middlefield Road
Mountain View, CA 94043
(650) 965-7873
info@igmbio.com